We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+13.19%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.1B
AUM Growth
+$1.25B
Cap. Flow
-$1.53B
Cap. Flow %
-12.71%
Top 10 Hldgs %
75.84%
Holding
141
New
6
Increased
25
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$90.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$52.6M
3
DYAX
DYAX CORPORATION
DYAX
+$24.1M
4
ALKS icon
Alkermes
ALKS
+$17.5M
5
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$15.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$18.6M
2
XNPT
XENOPORT, INC.
XNPT
+$17M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$16.8M
4
RPRX
Repros Therapeutics Inc.
RPRX
+$14.5M
5
LRMR icon
Larimar Therapeutics
LRMR
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 73.26%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPZM
76
DELISTED
Epizyme, Inc
EPZM
$3.72M 0.03%
232,481
– –
IONS icon
77
Ionis Pharmaceuticals
IONS
$8.97B
$3.54M 0.03%
57,140
– –
JUNO
78
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.52M 0.03%
80,000
– –
VTAE
79
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$3.4M 0.03%
187,597
– –
NBRV
80
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.37M 0.03%
1,400
– –
SRRA
81
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.01M 0.02%
5,000
– –
IMDZ
82
DELISTED
Immune Design Corp.
IMDZ
$2.99M 0.02%
148,937
– –
KPTI icon
83
Karyopharm Therapeutics
KPTI
$156M
$2.88M 0.02%
14,466
– –
AFMD
84
DELISTED
Affimed
AFMD
$2.85M 0.02%
40,000
– –
FLXN
85
DELISTED
Flexion Therapeutics, Inc.
FLXN
$2.83M 0.02%
+146,642
New +$2.55M
ISEE
86
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.8M 0.02%
35,649
– –
NTRA icon
87
Natera
NTRA
$36.1B
$2.7M 0.02%
250,000
– –
TRIL
88
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.67M 0.02%
211,792
+148,778
+236% +$2.07M
ENTA icon
89
Enanta Pharmaceuticals
ENTA
$365M
$2.49M 0.02%
75,357
– –
NBSE
90
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$2.27M 0.02%
926
– –
STML
91
DELISTED
Stemline Therapeutics, Inc.
STML
$2.1M 0.02%
333,497
– –
SVRA icon
92
Savara
SVRA
$1.09B
$2.02M 0.02%
68,535
+1,286
+2% +$40K
IRWD icon
93
Ironwood Pharmaceuticals
IRWD
$598M
$1.96M 0.02%
201,981
– –
MDWD icon
94
MediWound
MDWD
$186M
$1.92M 0.02%
32,143
– –
ASMB icon
95
Assembly Biosciences
ASMB
$494M
$1.88M 0.02%
20,833
– –
DVAX
96
DELISTED
Dynavax Technologies
DVAX
$1.81M 0.02%
75,000
– –
AUPH icon
97
Aurinia Pharmaceuticals
AUPH
$1.94B
$1.79M 0.01%
711,499
– –
CYTR
98
DELISTED
CytRx Corp
CYTR
$1.75M 0.01%
109,999
-109,999
-50% -$1.89M
CLLS
99
Cellectis
CLLS
$289M
$1.55M 0.01%
50,000
– –
MRNS
100
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.53M 0.01%
50,000
– –
2 3
4
5 6

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Baker Bros. Advisors held 141 positions worth $12.1B, up 12% from $10.8B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors withdrew a net $1.53B in Q4 2015, closing 8 positions and reducing 5 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $18.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 74% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alkermes worth $19.9M.

  • Baker Bros. Advisors's largest Q4 2015 buy was Alkermes: 250,251 shares worth $19.9M.
  • Baker Bros. Advisors added most to Acorda Therapeutics in Q4 2015, an estimated $90.4M increase.
  • Baker Bros. Advisors's biggest Q4 2015 reduction was XENOPORT, INC., cutting an estimated $17M.
  • Baker Bros. Advisors fully exited Clovis Oncology, Inc. in Q4 2015, selling an estimated $18.6M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $12.1B portfolio in Q4 2015.
  • Baker Bros. Advisors opened 6 new positions and closed 8 in Q4 2015.
  • Baker Bros. Advisors's portfolio value rose 12% quarter-over-quarter to $12.1B.

Based on Baker Bros. Advisors's 13F filing for Q4 2015, filed 16 Feb 2016.